🔧На сайте запланированы технические работы
25.12.2025 в промежутке с 18:00 до 21:00 по Московскому времени (GMT+3) на сайте будут проводиться плановые технические работы. Возможны перебои с доступом к сайту. Приносим извинения за временные неудобства. Благодарим за понимание!
🔧Site maintenance is scheduled.
Scheduled maintenance will be performed on the site from 6:00 PM to 9:00 PM Moscow time (GMT+3) on December 25, 2025. Site access may be interrupted. We apologize for the inconvenience. Thank you for your understanding!

 

Generation of a Vaccine against Group B Streptococcal Infection on the Basis of a Cold-Adapted Influenza A Virus


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

The aim of this study was to develop a cold-adapted influenza A (H7N9) strain-based vector vaccine expressing epitopes of conserved lipoprotein of Streptococcus agalactiae. Recombinant hemagglutinin (HA) genes of live attenuated influenza vaccine (LAIV) strain A/Anhui/1/2013(H7N9) with insertions of group B Streptococcus (GBS) surface antigen ScaAB gene parts of different length in-frame between signal peptide and HA1 were constructed by means of reverse genetics. Viral vector vaccine H7-ScaAB-85 expressing the shortest (85 amino acids) polypeptide from lipoprotein ScaAB linked to HA via a flexible linker was genetically stable, replicated in embryonated chicken eggs and MDCK cells at the same level as cold-adapted influenza A (H7N9) strain. An increase of ScaAB polypeptide insertion length up to 141 amino acids resulted in a decrease of the viral replication level in both susceptible systems and intense mutagenesis of hybrid HA-gene of recombinant influenza A virus in the gene region encoding foreign bacterial lipoprotein. These findings suggest that H7-ScaAB-85 is a promising vaccine candidate, which should be further assessed using a mouse model.

Sobre autores

T. Smolonogina

Institute of Experimental Medicine

Autor responsável pela correspondência
Email: smolonogina@mail.ru
Rússia, St. Petersburg, 197376

I. Isakova-Sivak

Institute of Experimental Medicine

Email: smolonogina@mail.ru
Rússia, St. Petersburg, 197376

T. Kotomina

Institute of Experimental Medicine

Email: smolonogina@mail.ru
Rússia, St. Petersburg, 197376

A. Evsina

Institute of Experimental Medicine

Email: smolonogina@mail.ru
Rússia, St. Petersburg, 197376

E. Stepanova

Institute of Experimental Medicine

Email: smolonogina@mail.ru
Rússia, St. Petersburg, 197376

P. Prokopenko

Institute of Experimental Medicine

Email: smolonogina@mail.ru
Rússia, St. Petersburg, 197376

G. Leontieva

Institute of Experimental Medicine

Email: smolonogina@mail.ru
Rússia, St. Petersburg, 197376

A. Suvorov

Institute of Experimental Medicine

Email: smolonogina@mail.ru
Rússia, St. Petersburg, 197376

L. Rudenko

Institute of Experimental Medicine

Email: smolonogina@mail.ru
Rússia, St. Petersburg, 197376

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML

Declaração de direitos autorais © Allerton Press, Inc., 2019